Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CYP11A1 inhibitor INV-9956

An orally bioavailable inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1; P450 11A1), with potential antineoplastic activity. Upon oral administration, CYP11A1 inhibitor INV-9956 selectively targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all steroid hormones and their precursors. This may inhibit the proliferation of hormone-positive tumor cells. CYP11A1, a mitochondrial enzyme, catalyzes the conversion of cholesterol to pregnenolone, which is the first rate-limiting step in steroid hormone biosynthesis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	INV 9956 INV-9956 INV9956

CYP11A1 inhibitor INV-9956

Search NCI's Drug Dictionary